SCHEMBL7914034

SCHEMBL7914034

CC(NC(=O)C1(c2ccc(F)cc2)CCN(C(=O)c2ccc(-c3ccc(F)cc3)cc2)CC1)c1ccccn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A7 Q99884 4/20 0.47
TACR3 P29371 2/20 0.45
L3MBTL1 Q9Y468 2/20 0.43
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
ABL1 P00519 1/20 0.41
BCR P11274 1/20 0.41
MAPK1 P28482 3/20 0.41
ALDH1A1 P00352 2/20 0.41
PKLR P30613 1/20 0.41
ROCK2 O75116 1/20 0.40
AKT1 P31749 1/20 0.40
AKT2 P31751 1/20 0.40
AKT3 Q9Y243 1/20 0.40
HSD11B1 P28845 1/20 0.40
IDO1 P14902 1/20 0.40
TSHR P16473 1/20 0.40
PRKAA2 P54646 1/20 0.40
CCR1 P32246 1/20 0.39
PPARG P37231 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7914036 0.88 SLC6A7 (0.45) SLC6A7TACR3L3MBTL1MEN1KMT2A
SCHEMBL13092254 0.84 KIT (0.44) SLC6A7MEN1KMT2AALDH1A1HSD11B1
SCHEMBL3714839 0.84 NPC1 (0.49) SLC6A7MEN1KMT2AHSD11B1TSHR
SCHEMBL378834 0.84 TACR1 (0.48) SLC6A7MEN1KMT2AHSD11B1TSHR
SCHEMBL13092323 0.81 CYP3A4 (0.47) SLC6A7MEN1KMT2AABL1BCR
SCHEMBL13092262 0.81 ALDH1A1 (0.47) SLC6A7MEN1KMT2AABL1BCR
SCHEMBL7910160 0.81 KMT2A (0.48) SLC6A7MEN1KMT2AMAPK1HSD11B1
SCHEMBL378786 0.80 MEN1 (0.46) SLC6A7MEN1KMT2AMAPK1HSD11B1
SCHEMBL13092423 0.80 SLC6A7 (0.50) SLC6A7TACR3L3MBTL1MEN1KMT2A
SCHEMBL2471039 0.80 GFER (0.44) ALDH1A1TSHRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8324250-B2 Piperidine derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-12-04 US disclosed
US-8324250-B2 Piperidine derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-12-04 US disclosed
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-10-07 US disclosed
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-10-07 US disclosed
WO-2010106081-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2010-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HTR3A, OPRL1, OPRK1 SLC6A7 105/4885TACR3 41/4885L3MBTL1 4603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.